Latest Breaking News On - Dietmar berger - Page 1 : comparemela.com

Sanofi's multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

FDA Grants Priority Review to Sarclisa for Multiple Myeloma

Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.

FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase